A Study of ABT-751 in Patients With Renal Cell Cancer
Ontology highlight
ABSTRACT: The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
DISEASE(S): Carcinoma, Renal Cell,Renal Cell Cancer
PROVIDER: 2010119 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA